Post Profile






New Clinical Trial Will Test Cancer Drug as Alzheimer's Treatment

The Alzheimer's Drug Discovery Foundation (ADDF) announces a $2.1 million grant awarded to R. Scott Turner, MD, PhD, of Georgetown University Medical Center to conduct a phase II clinical trial of low-dose nilotinib (marketed as Tasigna(r) for use as a cancer therapy) in patients with Alzheimer's disease.
read more

share

Related Posts


Alzheimer's Drug Discovery Foundation Supports Madera Biosciences With A Grant To Advance Novel Drug Candidates For Alzheimer's Disease

Health : Medical News Today

The Alzheimer's Drug Discovery Foundation (ADDF) announced that it has awarded a grant of $294,000 to Madera Biosciences, Inc. to develop small molecule drugs designed to clear accumulated beta-amyloid from the brain and thus halt o...

Alzheimer's Drug Discovery Foundation Supports Axxam To Develop Novel Therapeutics For Alzheimer's Disease

Health : Medical News Today

The Alzheimer's Drug Discovery Foundation (ADDF) announced that it has awarded a grant to Axxam SpA to develop small molecules to treat Alzheimer's disease by targeting inflammation. The award will fund a drug discovery project to i...

Lewy Body Dementia Association and the Alzheimer's Drug Discovery Foundation Award Two Grants to Support Promising Dementia Research

Health : Newswise Medical News

The Lewy Body Dementia Association and the Alzheimer's Drug Discovery Foundation have awarded $100,000 each to Omar El-Agnaf, PhD, of United Arab Amirates University and Michelle Mielke, PhD, of Mayo Clinic Rochester to provide one ...

Alzheimer's Drug Discovery Foundation Funds Development Of Clinical Tests For Alzheimer's Disease

Health : Medical News Today

The Alzheimer's Drug Discovery Foundation (ADDF) awarded the British firm of Cambridge Cognition Ltd. a grant of $200,000 to assist in their development of a clinical cognitive assessment product for Alzheimer's disease.

Georgetown Receives FDA Clearance to Conduct Clinical Trial with Nilotinib in Alzheimer's Disease

Health : Newswise Medical News

Georgetown University Medical Center today announces the U.S. Food and Drug Administration has completed its review of an investigational new drug application (IND) for the use of nilotinib in a phase II clinical trial for patients ...

Comments


Copyright © 2016 Regator, LLC